Recent trials suggest that lower doses of immunotherapy drugs like Keytruda may effectively enhance survival rates for cancer patients while reducing costs. Research indicates that reduced treatments could help patients in low-income countries, where full-priced therapies are often unaffordable. Experts advocate for reevaluating optimal dosing strategies for broader access.













